Oxford Biomedica (LON:OXB) Stock Passes Below Two Hundred Day Moving Average of $366.88

Shares of Oxford Biomedica plc (LON:OXB) crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of GBX 366.88 ($4.53) and traded as low as GBX 213 ($2.63). Oxford Biomedica shares last traded at GBX 213 ($2.63), with a volume of 156,290 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, Liberum Capital dropped their target price on shares of Oxford Biomedica from GBX 350 ($4.32) to GBX 310 ($3.83) and set a “hold” rating for the company in a research report on Tuesday, September 26th.

Oxford Biomedica Stock Performance

The stock has a market capitalization of £210.69 million, a price-to-earnings ratio of -332.81 and a beta of 0.95. The company’s fifty day simple moving average is GBX 269.82 and its 200 day simple moving average is GBX 366.88. The company has a quick ratio of 1.67, a current ratio of 3.32 and a debt-to-equity ratio of 57.10.

Insiders Place Their Bets

In related news, insider Dame Kay Davies bought 1,000 shares of the company’s stock in a transaction dated Tuesday, September 26th. The stock was purchased at an average price of GBX 291 ($3.59) per share, with a total value of £2,910 ($3,592.15). In other Oxford Biomedica news, insider Roch Doliveux purchased 36,130 shares of Oxford Biomedica stock in a transaction that occurred on Wednesday, September 20th. The stock was acquired at an average price of GBX 274 ($3.38) per share, with a total value of £98,996.20 ($122,202.44). Also, insider Dame Kay Davies acquired 1,000 shares of the company’s stock in a transaction on Tuesday, September 26th. The shares were bought at an average price of GBX 291 ($3.59) per share, for a total transaction of £2,910 ($3,592.15). Corporate insiders own 8.68% of the company’s stock.

About Oxford Biomedica

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems.